HeartBeam inc (BEAT)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
$0.39-6.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
QuarterlyIQ Insights · BEAT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
HeartBeam intends to achieve global adoption by partnering its breakthrough patented 3D ECG platform across the five channels that already have distribution, governments and national health systems,…
Stated in a supplied disclosure. Management reported: “HeartBeam intends to achieve global adoption by partnering its breakthrough patented 3D ECG platform across the five channels that already have distribution, governments and national health systems, ECG OEMs, Holter and patch manufacturers, health systems and integrated delivery networks, and consumer wearable companies, and by adapting its technology to the form factor each use case requires.” “With commercialization underway, the company is positioned to make that capability routine for the millions of Americans living with or at risk for arrhythmia,” said Dr. Vajdic.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A central focus of this strategy is expanding HeartBeam’s platform beyond arrhythmia assessment into reliable heart attack detection, which the company believes is one of the largest unmet needs in c…
Stated in a supplied disclosure. Management reported: “A central focus of this strategy is expanding HeartBeam’s platform beyond arrhythmia assessment into reliable heart attack detection, which the company believes is one of the largest unmet needs in cardiac care.” ““At the same time, we will continue to conduct the previously announced clinical studies to accelerate the development of our offering into a comprehensive detection platform for heart attack and other cardiac conditions beyond arrhythmia.””
The reorganization is expected to sharpen the Company’s focus on delivering results and create a meaningfully lower cost structure.
Stated in a supplied disclosure. Management reported: “The reorganization is expected to sharpen the Company’s focus on delivering results and create a meaningfully lower cost structure.” “This structure streamlines decision-making, improves accountability, and enables leadership to concentrate resources on achieving key milestones while maintaining disciplined management.”
Use proceeds from public offering to advance commercialization of FDA-cleared 12-lead synthesized ECG system and related initiatives.
Navigate CEO and CFO departures and ensure leadership continuity with new executive appointments and retention agreements.
Over the trailing year it converted 0.77x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.